Predict your next investment

Family Office
gisev.com

See what CB Insights has to offer

Investments

7

About Gisev Family Office

Gisev Family Office is a family office investor.

Gisev Family Office Headquarter Location

Contrada di Sassello 2

Lugano, 6900,

Switzerland

+41 9197328

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Gisev Family Office News

Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners

Oct 23, 2020

Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners Solarea Bio, a biotech company based in Cambridge, MA developing microbial-based solutions to aid human health, announced today it has raised $11.2M in a Series A financing led by S2G Ventures and Bold Capital Partners, along with continued investment from Viking Global and additional investment from the Gisev Family Office as a syndicate investor. Solarea has built a platform to rapidly identify novel products that address widespread chronic health disorders. The company has generated a large and unique database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Solarea’s first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being. Musculoskeletal disorders, including osteoporosis, osteopenia and osteoarthritis, are a leading cause of disability worldwide. In the U.S., approximately 10 million Americans are currently living with osteoporosis or osteopenia, and one in three women over age 50 will experience an osteoporosis related fracture. Tragically, hip fractures have a one-year mortality rate of 30% and a two-year of close to 56%. Solarea believes a natural, microbial-based solution will have a positive impact on the quality of life of millions of women worldwide who are at risk for these musculoskeletal disorders and aid in improving health outcomes. Solarea will use the proceeds from its Series A fundraise to advance its musculoskeletal product, SBD111, through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products. “We are very excited for Solarea to enter this stage with such a great team of investors. Our team is completely aligned in our view of the future of food as medicine and the process to develop and commercialize novel microbial-based solutions. We see a clear link between analyzing healthy foods and creating new products to improve the lives of patients in need,” says Gerardo V Toledo, Solarea’s CEO and Co-founder. Matthew Walker, Managing Director at S2G Ventures notes: “Solarea is developing products that combat diseases of inflammation through the gut microbiome in a way that works synergistically with the body and is backed by rigorous preclinical sudies. As we continue to see a convergence between food and medicine, we’re delighted to partner with Bold Capital, Viking Global, and the Gisev Family Office to help support this exceptional team in their mission to use food-based tools to improve human health.” Neal Bhadkamkar, General Partner at Bold comments: “Solarea is a quintessential Bold portfolio company – a passionate and deeply knowledgeable team seeking to create meaningful societal impact by harnessing the power of exponential technologies, in this case sequencing and computational biology. We are eager to see Solarea’s first products get to market and improve the bone health of millions of women and men worldwide. Bold Capital, Viking and other early investors stepped in to support Solarea as it left the Illumina Accelerator two years ago. We are thrilled to see the company take this next step in its journey with S2G Ventures and Gisev Family Office joining the investor group.” Sign Up to Free Newsletter The Microbiome Drug Database

Gisev Family Office Investments

7 Investments

Gisev Family Office has made 7 investments. Their latest investment was in Seed Health as part of their Series A on April 4, 2021.

CBI Logo

Gisev Family Office Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/21/2021

Series A

Seed Health

$40M

Yes

8VC, Artis Ventures, Founders Fund, and The Craftory

2

3/30/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/24/2020

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

9/14/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

9/11/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/21/2021

3/30/2021

11/24/2020

9/14/2020

9/11/2020

Round

Series A

Series A

Seed VC - II

Series A

Series A

Company

Seed Health

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$40M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

8VC, Artis Ventures, Founders Fund, and The Craftory

Sources

2

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.